Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.
Sign Up to like & getrecommendations! Published in 2020 at "European journal of cancer"
DOI: 10.1016/j.ejca.2020.04.044
Abstract: PURPOSE This study (NCT02083354) assessed the efficacy and safety of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma. METHOD Overall, 77 patients of East Asian origin (including 61 from Mainland… read more here.
Keywords: braf v600; cutaneous melanoma; v600 mutant; mutant cutaneous ... See more keywords